Trials / Completed
CompletedNCT06575595
Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010)
A Pharmacokinetic Study of Tulisokibart Administered Subcutaneously Via Autoinjector or Syringe in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objectives of the study are to characterize the pharmacokinetics (PK) of a single subcutaneous (SC) dose of tulisokibart (MK-7240) administered via autoinjector (AI) (Treatment A) and to characterize the PK of different concentrations of tulisokibart following SC administration of a single dose via vial/syringe (Treatments B and C). There is no formal hypothesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tulisokibart | single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C) |
Timeline
- Start date
- 2024-09-24
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
- First posted
- 2024-08-28
- Last updated
- 2025-02-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06575595. Inclusion in this directory is not an endorsement.